Chimeric: Media Thread, page-778

Great Newsletter , thanks for posting , I especially liked

.The early encouraging data was demonstrated in patients who had failed many early drugs and two surgeries, and who received CHM CLTX CAR-T, on average, as 4th line therapy and demonstrated a 55% Disease Control Rate (DCR), which means the cancer did not grow,~10 months survival in patients who achieved disease control and with a manageable safety profile. One patient lived for ~ 18 months , two patients exceeded 14 months survival and three patients remained alive and in follow up at the time of the announcements.

Notably, one patient maintained a complete response for over 15 months at the time of trial publication, which means the cancer did not grow back.

Company just need to keep up promotion and Rebecca is a great presenter , clear concise and engaging NZT